The usually reliable Reuters service put out an overnight story — on Hospira’s attempts (now owned by Pfizer) to launch a generic version of Invanz® (purporting to cover the patent spats involved) — that is (at best) confusing.
Here is the full memorandum opinion (a 49 page PDF file) from last Friday in Delaware federal District Court.
You should read it for yourself — but the upshot is that it will be immaterial to Kenilworth.
If and when I find some quiet time, I’ll be back to explain what’s really going on here. Until then — best to all. As ever, life intervenes — smile. . .